| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.094 | 0.01 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.01 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.02 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.02 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.03 |